CSIMarket
 
Abaxis Inc  (ABAX)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 24
 Employees 798
 Revenues (TTM) (Millions $) 245
 Net Income (TTM) (Millions $) 28
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 5

Abaxis Inc
Abaxis, Inc. is a developer, manufacturer, and marketer of portable blood analysis systems worldwide, which are used in various medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. It is also a leading global provider of veterinary point-of-care diagnostic products. Abaxis provides advanced technology, tools, and services that support best medical practices, allowing physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economically and profitably. Abaxis primarily offers point-of-care diagnostic instruments and consumables used in the medical and veterinary markets, including portable blood chemistry analysis systems that provide clinicians with rapid blood constituent measurements. The company also sells point-of-care diagnostic products, including instruments, consumables, and rapid tests, to help customers improve the efficiency and effectiveness of their healthcare operations. Abaxis is a California corporation founded in 1989, and its sales have increased over the years due to the growing installed base of its blood chemistry analyzers and the expansion of test methods provided to the medical and veterinary markets. The company has also expanded its diagnostic products and service offerings in the veterinary market. Abaxis previously provided veterinary reference laboratory diagnostic and consulting services for veterinarians through its Abaxis Veterinary Reference Laboratories ("AVRL") division. However, it sold substantially all of the assets of AVRL to Antech Diagnostics, Inc., the VCA laboratory division, for $21.0 million in cash pursuant to an asset purchase agreement in March 2015. The company has reclassified the assets and liabilities of AVRL as discontinued operations on its consolidated balance sheets for all periods presented, and the results of operations of AVRL as discontinued operations on its consolidated statements of income for all periods presented. On May 15, 2018, Abaxis entered into an Agreement and Plan of Merger with Zoetis Inc., a Delaware corporation, and Zeus Merger Sub, Inc., a California corporation, and an indirect wholly-owned subsidiary of Zoetis. Pursuant to the Merger Agreement, Merger Sub merged with and into Abaxis, with Abaxis continuing as the surviving corporation and a wholly-owned subsidiary of Zoetis. As a result of the Merger, each share of common stock, no par value, of Abaxis issued and outstanding immediately prior to the effective time of the Merger was converted into the right to receive $83.00 in cash, without interest, per share.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cytek Biosciences Inc

Cytek Biosciences Inc. Surges in Revenue, Defying Market Trends

CTKB, the leading cell analysis solutions company, has reported strong financial results for the fourth quarter and fiscal year 2023. The company showcased impressive growth, with income per share rising by 101.19% year on year to $0.04 per share and revenue increasing by 22.058% to $59.00 million.
This growth is particularly noteworthy considering the downward trend in the Laboratory Analytical Instruments sector. CTKB has defied industry peers, who experienced a decline in top-line revenue during the same period. Additionally, when compared sequentially, CTKB demonstrated positive progress, with income per share improving from $-0.05 per share and revenue increasing by 25.054% from $47.18 million.

Cue Health Inc

Cue Health Inc Faces Challenges Amid Declining Revenue and Inventory Decrease



The Laboratory Analytical Instruments company recently announced its financial results for the fiscal year ending December 31, 2023. The report highlighted a significant decline in revenue and a widening shortfall per share compared to the previous reporting season. Additionally, Cue Health Inc, a related company, also reported a substantial net loss and a decrease in inventories. These financial figures provide insights into the company's performance and potential future challenges.
Financial Results:
The Laboratory Analytical Instruments company's revenue for the period ending December 31, 2023, plunged by a staggering 87.193% to $18.80 million. This decline was accompanied by a significant increase in the shortfall per share, which reached $-0.93 compared to $-0.31 in the previous reporting season. While the sequential revenue growth of 7.559% from $17.48 million offers some optimism, the overall financial results are concerning.

Kewaunee Scientific Corporation

Company Weathered Revenue Contraction with Resilience in Recent Financial Report

The stock market is a dynamic and ever-changing landscape, with companies constantly striving to improve their financial standing and deliver value to their shareholders. In this regard, KEQU, also known as Kewaunee Scientific Corporation, has recently announced some truly astonishing income improvements.
According to their third-quarter financial report for 2024, KEQU reported an impressive income improvement of 240%, reaching an impressive $0.85 per share. This remarkable achievement is even more notable considering the backdrop of a fading revenue, which decreased by -24.321% to $46.03 million. Despite this decline, KEQU has managed to significantly boost its profitability, showcasing the company's strong financial management and strategic decision-making.

Harvard Bioscience Inc

Harvard Bioscience Inc Reports Mixed Results in Fourth Quarter of 20232.

Harvard Bioscience Inc, a leader in the Laboratory Analytical Instruments industry, recently released its financial results for the fourth quarter of 2023. While the company reported a surge in its deficit per share and a slight increase in revenue, it also noted a decline in operating earnings and an increase in net deficit. These results have raised questions about the company's performance and future prospects.
In the fourth quarter of 2023, Harvard Bioscience Inc saw its deficit per share increase to $-0.08 from $-0.04 in the previous year. The company also reported a net deficit of $-1.818 million, up from $-1.666 million in the same period a year ago. Despite a modest revenue growth of 0.946% to $28.70 million, the company experienced a decrease in operating earnings by -72.77% to $3.78 million, resulting in a lower operating margin of 13.17%.

Pacific Biosciences Of California Inc

Pacific Biosciences Of California Inc's Remarkable Revenue Growth Raises Concerns About Operational Efficiency

As a Wall Street journalist, it is important to analyze and dissect the financial performance of companies to provide investors with valuable insights. In the case of Pacific Biosciences Of California Inc, the recent announcement of very solid revenue growth of 113.622% year on year to $58.43 million in the October to December 31, 2023 three months is indeed impressive. However, it is concerning to note that the company reported a net loss of $-0.28 per share during this period.
Despite the strong revenue growth, Pacific Biosciences Of California Inc's behavior is surprising, especially when compared to the rest of the Laboratory Analytical Instruments industry, which experienced a decline in revenue by -4.40%. This raises questions about the company's operational efficiency and profitability.






 

Abaxis Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com